Biodesix Q1 2024 GAAP EPS $(0.14), Inline, Sales $14.818M Beat $14.180M Estimate
Portfolio Pulse from Benzinga Newsdesk
Biodesix (NASDAQ:BDSX) reported Q1 2024 GAAP EPS of $(0.14), meeting analyst consensus estimates and marking a 41.67% improvement over last year's $(0.24) per share. Quarterly sales reached $14.818M, exceeding the $14.180M estimate by 4.50% and representing a 63.63% increase from the previous year's $9.056M.
May 08, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biodesix reported Q1 2024 earnings with EPS of $(0.14), in line with estimates, and sales of $14.818M, surpassing expectations. Year-over-year improvements in both earnings and sales were significant.
Meeting EPS estimates and exceeding sales forecasts, especially with significant year-over-year growth, is likely to be viewed positively by investors. This performance indicates operational efficiency and market demand for Biodesix's offerings, potentially leading to increased investor confidence and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100